International Stem Cell (ISCO) Free Cash Flow (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Free Cash Flow of $29000.0 for Q4 2025, up 112.13% year-over-year from $13670.6 in Q4 2024, and down 36.96% quarter-over-quarter from $46000.0 in Q3 2025.
International Stem Cell (ISCO) Free Cash Flow (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Free Cash Flow for 16 consecutive years, with $29000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 112.13% year-over-year to $29000.0; the TTM figure through Dec 2025 stood at -$35000.0 (up 77.12% YoY), while the FY2025 annual figure was -$35000.0, up 77.12% from the prior year.
- Free Cash Flow eased to $29000.0 in Q4 2025 per ISCO's latest filing, from $46000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $439000.0 in Q2 2023 and bottomed at -$394000.0 in Q1 2021.
- Historically, Free Cash Flow has averaged -$15700.0 across 5 years, with a median of $37500.0 in 2025.
- Annual changes were most pronounced in 2021 — Free Cash Flow slumped 881.08% — and 2023, when it jumped 973.91%.
- International Stem Cell's Free Cash Flow stood at -$326000.0 in 2021, then jumped by 124.23% to $79000.0 in 2022, then surged by 103.8% to $161000.0 in 2023, then plunged by 248.45% to -$239000.0 in 2024, then jumped by 112.13% to $29000.0 in 2025.
- Business Quant data shows ISCO's Free Cash Flow at $29000.0 in Q4 2025, $46000.0 in Q3 2025, and -$332000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | -332,000.00 |
| Jun 30, 2025 | -332,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Dec 31, 2024 | -239,000.00 |
| Dec 31, 2024 | -239,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | -103,000.00 |
| Jun 30, 2024 | -103,000.00 |
| Mar 31, 2024 | -195,000.00 |
| Mar 31, 2024 | -195,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Sep 30, 2023 | 48,000.00 |
| Sep 30, 2023 | 48,000.00 |